ME03485B - Derivati benzimidazola kao inhibitori bromodomena - Google Patents
Derivati benzimidazola kao inhibitori bromodomenaInfo
- Publication number
- ME03485B ME03485B MEP-2019-171A MEP2019171A ME03485B ME 03485 B ME03485 B ME 03485B ME P2019171 A MEP2019171 A ME P2019171A ME 03485 B ME03485 B ME 03485B
- Authority
- ME
- Montenegro
- Prior art keywords
- flomdomain
- inhibitors
- benzimidazole derivatives
- benzimidazole
- derivatives
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
| PCT/EP2016/055792 WO2016146738A1 (en) | 2015-03-19 | 2016-03-17 | Benzimidazole derivatives as bromodomain inhibitors |
| EP16710214.4A EP3271349B1 (en) | 2015-03-19 | 2016-03-17 | Benzimidazole derivatives as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03485B true ME03485B (me) | 2020-01-20 |
Family
ID=53052091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-171A ME03485B (me) | 2015-03-19 | 2016-03-17 | Derivati benzimidazola kao inhibitori bromodomena |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10442786B2 (me) |
| EP (2) | EP3271349B1 (me) |
| JP (1) | JP6419990B2 (me) |
| KR (1) | KR102072850B1 (me) |
| CN (1) | CN107635989B (me) |
| AR (1) | AR103934A1 (me) |
| AU (1) | AU2016232217B2 (me) |
| BR (1) | BR112017019779B1 (me) |
| CA (1) | CA2979504C (me) |
| CL (1) | CL2017002332A1 (me) |
| CO (1) | CO2017009992A2 (me) |
| CR (1) | CR20170430A (me) |
| CY (1) | CY1121855T1 (me) |
| DK (1) | DK3271349T3 (me) |
| DO (1) | DOP2017000213A (me) |
| EA (1) | EA033594B1 (me) |
| ES (1) | ES2735417T3 (me) |
| GB (1) | GB201504689D0 (me) |
| HR (1) | HRP20191186T1 (me) |
| HU (1) | HUE044414T2 (me) |
| IL (1) | IL254318B (me) |
| LT (1) | LT3271349T (me) |
| MA (2) | MA41778A (me) |
| ME (1) | ME03485B (me) |
| MX (1) | MX2017012023A (me) |
| PE (1) | PE20180032A1 (me) |
| PH (1) | PH12017501620A1 (me) |
| PL (1) | PL3271349T3 (me) |
| PT (1) | PT3271349T (me) |
| RS (1) | RS59056B1 (me) |
| SG (1) | SG11201707356QA (me) |
| SI (1) | SI3271349T1 (me) |
| SM (1) | SMT201900428T1 (me) |
| TW (1) | TW201706257A (me) |
| UY (1) | UY36589A (me) |
| WO (1) | WO2016146738A1 (me) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| EP3334717B1 (en) | 2015-08-11 | 2020-07-01 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| WO2017024412A1 (en) | 2015-08-12 | 2017-02-16 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| WO2018195155A1 (en) * | 2017-04-18 | 2018-10-25 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| US20210261539A1 (en) * | 2018-02-06 | 2021-08-26 | Shanghai Haihe Pharmaceutical Co., Ltd. | Compound having bet inhibitory activity and preparation method and use therefor |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| CN119684285A (zh) * | 2019-03-15 | 2025-03-25 | 福马治疗股份有限公司 | 抑制环amp-应答元件结合蛋白(creb) |
| JP7603613B2 (ja) * | 2019-04-24 | 2024-12-20 | コンバージーン・リミテッド・ライアビリティ・カンパニー | 小分子ブロモドメイン阻害剤およびそれらの使用 |
| WO2020223370A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating schistosoma infections |
| CN116217416A (zh) * | 2022-12-31 | 2023-06-06 | 黄淮学院 | 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法 |
| AU2024279724A1 (en) * | 2023-05-30 | 2025-12-11 | 16380026 Canada Inc. | Cyp26b1 inhibitor compounds and methods of use thereof |
| CN119219631B (zh) * | 2024-12-04 | 2025-04-18 | 山东大学 | 一种bet蛋白溴结构域bd1选择性共价抑制剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| DK2007752T3 (da) | 2006-03-31 | 2010-11-15 | Janssen Pharmaceutica Nv | Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren |
| WO2011056635A1 (en) * | 2009-10-27 | 2011-05-12 | Glaxosmithkline Llc | Benzimidazoles as fatty acid synthase inhibitors |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| SI2624696T1 (sl) | 2010-10-06 | 2017-04-26 | Glaxosmithkline Llc Corporation Service Company | Benzimidazolni derivati kot inhibitorji pi3-kinaze |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| CN105073744B (zh) * | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
| SMT201800650T1 (it) | 2013-03-15 | 2019-01-11 | Plexxikon Inc | Composti eterociclici e loro impiego |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015004533A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko not_active Expired - Fee Related
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt active IP Right Grant
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 CA CA2979504A patent/CA2979504C/en active Active
- 2016-03-17 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/me unknown
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/en active Active
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 SM SM20190428T patent/SMT201900428T1/it unknown
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/en not_active Ceased
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja not_active Expired - Fee Related
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh active Active
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/en not_active Withdrawn
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03485B (me) | Derivati benzimidazola kao inhibitori bromodomena | |
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| EP3558969C0 (en) | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| DK3286183T3 (da) | Isoxazolylsubstituerede benzimidazoler | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| MA53944A (fr) | Inhibiteurs de la glycosidase | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| EP3183255C0 (en) | SPIROPYRROLIDINES USEFUL AS MDM2 INHIBITORS | |
| DK3286177T3 (da) | Quinolinderivater som tam rtk-inhibitorer | |
| ME03414B (me) | Imidazopirazinoni kао pde1 inhibitori | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3458460T3 (da) | Imidazoler som histondemethylase-inhibitorer | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| HUE048321T2 (hu) | Karabazol származékok | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| EP3303283A4 (en) | Fto inhibitors | |
| LT3371168T (lt) | Indolin-2-ono dariniai |